文献速递妇科

COVID-19疫情期间土耳其妇科癌症大手术患者围手术期SARS-CoV-2感染率:全国队列研究

Perioperative SARS-CoV-2 infection among women undergoing major gynecologic cancer surgery in the COVID-19 era: A nationwide, cohort study from Turkey.
PubMed 文献 · Gynecol Oncol · 2020-11-17

该回顾性全国队列研究检索土耳其卫生部数据库,纳入2020年3月11日至4月30日期间接受大手术的688例妇科癌症患者。围手术期SARS-CoV-2感染率为46/688(6.7%),其中45/46(97.8%)为术后确诊,COVID-19患者30天死亡率为0%。结论认为在严格感染控制措施下,妇科癌症手术可接受围手术期感染率。

要点

  • 妇科癌症大手术围手术期SARS-CoV-2感染率为6.7%(46/688)。
  • 97.8%(45/46)感染在术后确诊,仅1例术前确诊。
  • COVID-19患者30天死亡率为0%,ICU入住率8.7%。

核心结论

  • 在COVID-19时代,若医护人员和患者严格遵守既定感染控制措施,妇科癌症手术可在可接受的围手术期SARS-CoV-2感染率下进行。

研究设计与样本

  • 回顾性、全国性队列研究,检索土耳其卫生部数据库,纳入2020年3月11日至4月30日期间接受大手术的688例妇科癌症患者,纳入标准严格基于最终组织病理学诊断为恶性妇科肿瘤。

主要发现

  • 研究期间全国共识别688例接受大手术的妇科癌症女性,中位年龄59岁。
  • 手术方式以开腹为主(634/688,92.2%)。
  • 癌症类型分布:子宫内膜癌410例(59.6%)、卵巢癌195例(28.3%)、宫颈癌66例(9.6%)、外阴癌14例(2.0%)、子宫肉瘤3例(0.4%)。
  • 围手术期(术前7天内或术后30天内)确诊SARS-CoV-2感染率为46/688(6.7%)。
  • 46例感染者中45例(97.8%)为术后确诊,ICU入住率为4/46(8.7%),有创机械通气率为2/46(4.3%),30天死亡率为0%。

临床怎么用

  • 在COVID-19疫情期间,妇科癌症大手术可在严格感染控制措施下开展,围手术期感染率处于可接受水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to determine the rate of perioperative SARS-CoV-2 infection among gynecologic cancer patients undergoing major surgery. METHODS: The database of the Turkish Ministry of Health was searched in order to identify all consecutive gynecologic cancer patients undergoing major surgery between March 11, 2020 and April 30, 2020 for this retrospective, nationwide, cohort study. The inclusion criteria were strictly founded on a final histopathological diagnosis of a malignant gynecologic tumor. COVID-19 cases were diagnosed by reverse transcriptase- polymerase chain reaction testing for SARS-CoV-2. The rate of perioperative SARS-CoV-2 infection and the 30-day mortality rate of COVID-19 patients were investigated. RESULTS: During the study period, 688 women with gynecologic cancer undergoing major surgery were identified nationwide. The median age of the patients was 59 years. Most of the surgeries were open (634/688, 92.2%). There were 410 (59.6%) women with endometrial cancer, 195 (28.3%) with ovarian cancer, 66 (9.6%) with cervical cancer, 14 (2.0%) with vulvar cancer and 3 (0.4%) with uterine sarcoma. The rate of SARS-CoV-2 infections confirmed within 7 days before or 30 days after surgery was 46/688 (6.7%). All but one woman was diagnosed postoperatively (45/46, 97.8%). The rates of intensive care unit admission and invasive mechanical ventilation were 4/46 (8.7%) and 2/46 (4.3%), respectively. The 30-day mortality rate was 0%. CONCLUSION: In the COVID-19 era, gynecologic cancer surgery may be performed with an acceptable rate of perioperative SARS-CoV-2 infection if the staff and the patients strictly adhere to the established infection control measures.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ayhan A, Oz M, Topfedaisi Ozkan N, et al. Perioperative SARS-CoV-2 infection among women undergoing major gynecologic cancer surgery in the COVID-19 era: A nationwide, cohort study from Turkey. Gynecol Oncol. 2020. PMID: 33223221. doi:10.1016/j.ygyno.2020.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。